Stockscreener 앱 받기
69.21
0.01%
0.010
Ani Pharmaceuticals Inc 주식(ANIP)의 최신 뉴스
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Ani Pharmaceuticals Sr. VP sells $27,583 in stock By Investing.com - Investing.com Canada
Deep Dive Into ANI Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
ANI Pharmaceuticals (ANIP) Set for Potential Earnings Beat - GuruFocus
ANI Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 9, 2025, at 8:00 a.m. ET - GlobeNewswire
ANI Pharmaceuticals Reveals Q1 2025 Earnings Date: Key Executive Insights Coming May 9 - Stock Titan
Zacks.com featured highlights ANI Pharmaceuticals, Expand Energy, Avista Corp and Contango ORE - Yahoo Finance
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Tariff Woes? Play Safe With 4 Low-Beta Stocks: ANIP, EXE, AVA & CTGO - TradingView
ANI Pharmaceuticals at RBC Conference: Strategic Growth in Rare Diseases By Investing.com - Investing.com Canada
Is The Options Market Predicting A Spike In ANI Pharmaceuticals (ANIP) Stock? - Barchart.com
Is the Options Market Predicting a Spike in ANI Pharmaceuticals (ANIP) Stock? - Yahoo Finance
ANI Pharmaceuticals To Present At RBC Capital Markets Conference; Webcast At 7:45 AM ET - Nasdaq
Zacks.com featured highlights include HIS, ANI Pharmaceuticals, Pediatrix Medical, Fresenius Medical Care and LendingTree - Yahoo Finance
ANI Pharmaceuticals to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - GlobeNewswire
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio - TradingView
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross? - Zacks Investment Research
Alimera Sciences announces change to SmPC allowing all United Kingdom (Great Britain and Northern Ireland) qualified ophthalmic healthcare professionals experienced in intravitreal injections to administer ILUVIEN - PharmiWeb.com
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
ANI Pharmaceuticals Launches Kionex Suspension For Electrolyte Imbalance Management: Key Trend Transforming... - WhaTech
ANI Pharmaceuticals launches generic Nitazoxanide Tablets By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Launches Nitazoxanide Tablets for Treating Diarrhea -March 19, 2025 at 09:33 am EDT - MarketScreener
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets - GlobeNewswire
ANI Pharmaceuticals launches generic Nitazoxanide Tablets - Investing.com
ANI Pharmaceuticals Announces The Launch Of Nitazoxanide Tablets -March 19, 2025 at 06:51 am EDT - Marketscreener.com
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
ANI Pharmaceuticals settles royalty obligation for $17.25 million By Investing.com - Investing.com Australia
ANI Pharmaceuticals Eliminates Royalty Obligation On ILUVIEN And YUTIQ - Nasdaq
ANI Pharmaceuticals settles royalty obligation for $17.25 million - Investing.com India
ANI Pharma buys Iluvien and Yutiq royalties (ANIP:NASDAQ) - Seeking Alpha
ANI Pharma buys royalties linked to Iluvien and Yutiq - MSN
ANI Pharmaceuticals Completes Buyout of Royalty Obligation for Iluvien, Yutiq -March 18, 2025 at 08:20 am EDT - Marketscreener.com
ANI Pharmaceuticals Completes $17.25 Million Buyout of Royalty Obligation for ILUVIEN and YUTIQ - Nasdaq
ANI Pharmaceuticals Announces Buyout Of Royalty Obligation For Iluvien And Yutiq -March 18, 2025 at 06:55 am EDT - Marketscreener.com
ANI Pharmaceuticals Announces Buyout of Royalty Obligation for ILUVIEN® and YUTIQ® - GlobeNewswire
ANI Pharma's Strategic $17M Move Boosts Profit Potential for Eye Drug Portfolio - Stock Titan
Jefferies Initiates Coverage of ANI Pharmaceuticals (ANIP) with Buy Recommendation - Nasdaq
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock - Investing.com India
Ani Pharmaceuticals sr. VP Cook sells $25,332 in stock By Investing.com - Investing.com South Africa
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts - Benzinga
ANI Pharma rises on expanded US approval for eye-disease drug - TradingView
ANI Pharmaceuticals Says FDA Approves Expanded Label for Iluvien -March 14, 2025 at 07:23 am EDT - Marketscreener.com
Jefferies Initiates Coverage on ANI Pharmaceuticals With Buy Rating, $80 Price Target - Marketscreener.com
ANI Pharmaceuticals Announces FDA Approval for Expansion of ILUVIEN® Label - GlobeNewswire
ILUVIEN Scores Major FDA Win: Now Treats Two Serious Eye Conditions - StockTitan
0.74%
0.80%
자본화:
|
볼륨(24시간):